🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — anyone have experience? Page 3

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — anyone have experience?

MeganSA_TX Tue, Jan 9, 2024 at 10:31 AM 18 replies 2,325 viewsPage 3 of 4
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Jan 9, 2024 at 2:46 PM#11
Dr.GastroMayo said:
SURPASS-CVOT tirzepatide is not that straightforward in my experience

This is exactly right. Dr.GastroMayo articulated what I have been trying to explain to my doctor for months. The SURPASS-CVOT tirzepatide aspect is the most important factor.

Last edited: Jan 9, 2024 at 3:46 PM
50 17Dr.SurgeonPGH, rachel_ABQ, traveltech_sara and 47 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jan 9, 2024 at 3:03 PM#12

Reading this thread on SURPASS-CVOT tirzepatide hits close to home. Night shift nurse — I started at 291 lbs and felt like I would tried everything.

7 months on tirz and I am a different person. Not just the 66 lbs lost — my energy, my mood, my relationship with food. All transformed.

If you are on the fence about SURPASS-CVOT — take the leap. It was the best health decision I have ever made. ❤️

14 18Dr.GutHealth, amsterdam_pete, LondonLisa and 11 others
Reply Quote Save Share Report
HealthEcon_DC
Member
567
3,456
Apr 2024
Washington, DC
Jan 9, 2024 at 3:20 PM#13

Dr.AddMedPHL — that is really helpful context on SURPASS-CVOT tirzepatide. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

41 17KevinCompounds, TirzTom, TrialTracker_MD and 38 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Jan 9, 2024 at 3:37 PM#14

To answer PharmacoVig_BOS's question specifically:

From a clinical standpoint, SURPASS-CVOT tirzepatide is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

18 10lori_vegas, Dr.PulmRoch, maya_sedona and 15 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Jan 9, 2024 at 3:54 PM#15

Bookmarked 📌 The SURPASS-CVOT info in this thread is essential. Coming back to this for sure.

47 1FranDenver, Dr.BariatricHTX, LindaRN_retired and 44 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register